Butyrate (Sodium/Calcium Butyrate) 관련 Crohn's Disease
COral butyrate (4 g/day for 8 weeks) improved CDAI scores in open-label study. Controlled evidence still limited.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dbutyrate\u0026condition\u003Dibd\u002Dcrohns\u002Ddisease';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
C
결론
Oral butyrate (4 g/day for 8 weeks) improved CDAI scores in open-label study. Controlled evidence still limited.
Key Study Findings
Randomized Controlled Trial
n=140
Double-blind
Impact of oral butyrate on clinical and biochemical parameters in IBD: A randomized placebo-controlled study …
Dose: None
vs: placebo plus conventional therapy
Outcome: clinical disease activity and fecal calprotectin
효과: None
p=0.013
대상 집단: IBD patients (60 Crohn's disease, 80 ulcerative colitis)
In Vitro
Sodium butyrate alleviates DSS-induced inflammatory bowel disease by inhibiting ferroptosis and modulating ERK/STAT3 signaling and …
Dose: Low-dose and high-dose NaB
vs: DSS-induced IBD mice; 5-ASA control
Outcome: IBD symptom alleviation and ferroptosis inhibition
효과: None
None
대상 집단: DSS-induced IBD murine model
In Vitro
Effects of Lactobacillus paracei JY062 Postbiotic on Intestinal Barrier, Immunity, and Gut Microbiota.
Dose: 5 mg/mL
vs: LPS-treated cell models
Outcome: Intestinal barrier function and gut microbiota
효과: None
None
대상 집단: Caco-2 cells, RAW264.7 macrophages, fecal fermentation
Other
Association of Inflammatory Factors and Calcium Metabolism With Arthritis in Patients With Inflammatory Bowel Disease: …
Dose: None
vs: None
Outcome: Causal associations IBD → arthritis subtypes (MR)
효과: OR=1.21 (IBD→AS); OR=1.18 (IBD→PsA)
<0.001 (AS); 0.007 (PsA)
대상 집단: Mendelian randomization study of IBD and arthritis
Observational Study
n=212
Microbiome multi-omics analysis reveals novel biomarkers and mechanisms linked with CD etiopathology.
Dose: None
vs: Healthy controls
Outcome: CD-specific microbiome signatures (AUC 0.94)
효과: AUC 0.94 in external validation
None
대상 집단: Crohn's disease and ulcerative colitis patients
In Vitro
Effects of senotherapeutics on gut microbiome dysbiosis and intestinal inflammation in Crohn's disease: A pilot …
Dose: None
vs: Untreated Crohn's disease microbiota
Outcome: Gut microbiome modulation and inflammation
효과: None
None
대상 집단: Crohn's disease fecal microbiota in SHIME model
Key Statistics
2
연구
200
참여자
↑
Positive
C
등급
Referenced Papers
Digestive and liver …
2026
5 인용
Annals of medicine
2025
12 인용
Nutrients
2025
7 인용
Biomarker research
2025
6 인용
Translational research : …
2025
4 인용
Langenbeck's archives of …
2025
3 인용
Mediators of inflammation
2025
2 인용
BioFactors (Oxford, England)
2025
Frontiers in bioscience …
2025
ACS nano
2024
89 인용
Gut microbes
2024
32 인용
Gut microbiota and metabolites as predictors of biologics response in inflammatory bowel disease: A comprehensive systematic review.
Systematic Review
Microbiological research
2024
31 인용
International immunopharmacology
2024
17 인용
The American journal …
2024
11 인용
Cellular and molecular …
2024
10 인용
Poultry science
2024
9 인용
Inflammatory bowel diseases
2024
5 인용
Nutrients
2024
3 인용
Journal of animal …
2024
Nutrients
2023
162 인용
Digestion
2023
71 인용
Gut microbes
2023
29 인용
Microbiome
2023
28 인용
Lipids in health …
2023
7 인용
Gut microbes
2022
107 인용
Gut microbes
2022
60 인용
Nutrients
2022
54 인용
Journal of Crohn's …
2022
23 인용
Inflammatory bowel diseases
2022
21 인용
PloS one
2022
9 인용
International journal of …
2021
17 인용
Neurogastroenterology and motility
2020
176 인용
Journal of Crohn's …
2020
50 인용
Gut microbes
2020
32 인용
Frontiers in immunology
2019
3034 인용
Gastroenterology
2019
276 인용
Scientific reports
2019
124 인용
Terapevticheskii arkhiv
2019
50 인용
World journal of …
2019
45 인용
Current opinion in …
2019
5 인용
Current pharmaceutical design
2018
108 인용
Journal of Crohn's …
2018
91 인용
PLoS computational biology
2018
29 인용
Journal of animal …
2018
15 인용
Cell host & …
2017
399 인용
Scientific reports
2017
391 인용
Gastroenterology
2017
335 인용
Best practice & …
2017
14 인용
Innate immunity
2017
13 인용
Digestion
2016
522 인용
Journal of gastroenterology
2016
49 인용
Recent advances in characterizing the gastrointestinal microbiome in Crohn's disease: a systematic review.
Systematic Review
Inflammatory bowel diseases
2015
222 인용
Proceedings of the …
2014
1853 인용
Gut
2014
1657 인용
Gut
2013
311 인용
Polish journal of …
2013
PloS one
2012
108 인용
Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives.
Other
Gut
2011
1055 인용
Alimentary pharmacology & …
2005
227 인용
Alimentary pharmacology & …
2003
179 인용
Current opinion in …
2001
45 인용
Current opinion in …
2001
38 인용
Gut
2000
370 인용
Current opinion in …
2000
21 인용
Diseases of the …
1998
26 인용
The Journal of …
1994
29 인용
Digestive diseases (Basel, …
1993
29 인용
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
일반적으로 사용되는 용량
- general:
- 150-600 mg/day sodium or calcium butyrate
- ibdsupport:
- 300-600 mg three times daily (900-1,800 mg/day)
- butyrateenema:
- 100 mM butyrate enema for distal UC (clinical setting only)
상한량: No established upper limit for oral supplements; most studies use 600-4,000 mg/day
연구에서 사용된 용량
| 용량 | 기간 | 효과 | N |
|---|---|---|---|
| None | -- | Positive | 140 |
| Low-dose and high-dose NaB | -- | Positive | -- |
| 5 mg/mL | -- | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Positive | 212 |
| None | -- | Positive | -- |
| None | -- | Negative | -- |
| None | -- | Mixed | -- |
권장 복용 시간: With meals; enteric-coated formulations recommended to reach the colon
Safety & Side Effects
보고된 부작용
- ⚠ Unpleasant taste/odor (butyric acid has a strong rancid butter smell)
- ⚠ Mild GI discomfort (nausea, bloating)
- ⚠ Belching with butyric acid odor
- ⚠ Enteric-coated formulations reduce taste issues
알려진 상호작용
- ● 5-ASA medications (mesalamine) — additive anti-inflammatory effect (potentially beneficial in IBD)
- ● No significant adverse drug interactions known
일일 최대 섭취 허용량: No established upper limit for oral supplements; most studies use 600-4,000 mg/day
건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.
Frequently Asked Questions
Does Butyrate (Sodium/Calcium Butyrate) help with Crohn's Disease?
Based on 2 studies with 200 participants, there is limited but promising evidence that Butyrate (Sodium/Calcium Butyrate) may support Crohn's Disease management. Our evidence grade is C (Some Evidence).
How much Butyrate (Sodium/Calcium Butyrate) should I take for Crohn's Disease?
Studies have used various dosages. A commonly studied range is 150-600 mg/day sodium or calcium butyrate. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Butyrate (Sodium/Calcium Butyrate)?
Reported side effects may include Unpleasant taste/odor (butyric acid has a strong rancid butter smell), Mild GI discomfort (nausea, bloating), Belching with butyric acid odor, Enteric-coated formulations reduce taste issues. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Butyrate (Sodium/Calcium Butyrate) and Crohn's Disease?
We rate the evidence as Grade C (Some Evidence). This rating is based on 2 peer-reviewed studies with 200 total participants. The overall direction of effect is positive.
Related Evidence
관련 다른 성분: Crohn's Disease
Butyrate (Sodium/Calcium Butyrate) 다른 건강 상태에 대한 근거
FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.